Mazahir Alimohamed
Stock Analyst at Oppenheimer
(0.32)
# 4,553
Out of 5,090 analysts
20
Total ratings
26.3%
Success rate
-16.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mazahir Alimohamed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $22 → $16 | $2.62 | +510.69% | 4 | Oct 20, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $100 | $74.85 | +33.60% | 4 | Oct 2, 2026 | |
| CNTB Connect Biopharma Holdings | Rated: Buy | $8 → $5 | $0.8022 | +523.29% | 2 | Sep 22, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 → $40 | $21.07 | +89.84% | 3 | Sep 22, 2026 | |
| IRLA IRulya Therapeutics | Reiterated: Buy | $82 | $32.95 | +148.86% | 1 | Aug 17, 2026 | |
| IKT Inhibikase Therapeutics | Reiterated: Buy | $5 | $1.55 | +222.58% | 2 | Aug 12, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $9 | $1.66 | +442.17% | 3 | Jul 20, 2026 | |
| EWTX Edgewise Therapeutics | Initiated Coverage: Buy | $51 | $38.90 | +31.11% | 1 | Jul 9, 2026 |
BridgeBio Oncology Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $22 → $16
Current: $2.62
Upside: +510.69%
Tarsus Pharmaceuticals
Oct 2, 2026
Reiterated: Buy
Price Target: $100
Current: $74.85
Upside: +33.60%
Connect Biopharma Holdings
Sep 22, 2026
Rated: Buy
Price Target: $8 → $5
Current: $0.8022
Upside: +523.29%
Tyra Biosciences
Sep 22, 2026
Reiterated: Buy
Price Target: $50 → $40
Current: $21.07
Upside: +89.84%
IRulya Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $82
Current: $32.95
Upside: +148.86%
Inhibikase Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $5
Current: $1.55
Upside: +222.58%
InflaRx
Jul 20, 2026
Reiterated: Buy
Price Target: $9
Current: $1.66
Upside: +442.17%
Edgewise Therapeutics
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $38.90
Upside: +31.11%